Answers are grounded in this paper and cite their sources.
NGS assessment reveals persistent MRD in long-term CLL survivors, indicating potential relapse risks.
We performed next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment in 17 patients with chronic lymphocytic leukemia (CLL) in remission at a median of 15.7 years post fludarabine, cyclophosphamide, and rituximab (FCR) and identified persistent MRD in 13/17 (76%) patients.
No takes yet. Share an insight, caveat, or question.
Bazinet et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: